Bimekizumab in psoriatic arthritis: a great leap forward?

Affiliations

¹ Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo 33011, Spain; Division of Translational Immunology, Health Research Institute of the Principality of Asturias, Oviedo, Spain; Faculty of Medicine, Oviedo University, Oviedo, Spain. Electronic address: rubenque7@yahoo.es.

Comment

Rubén Queiro. Lancet. 2023.

. 2023 Jan 7;401(10370):2-3.

doi: 10.1016/S0140-6736(22)02423-0. Epub 2022 Dec 6.

¹ Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo 33011, Spain; Division of Translational Immunology, Health Research Institute of the Principality of Asturias, Oviedo, Spain; Faculty of Medicine, Oviedo University, Oviedo, Spain. Electronic address: rubenque7@yahoo.es.

No abstract available

Comment on

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ. McInnes IB, et al. Lancet. 2023 Jan 7;401(10370):25-37. doi: 10.1016/S0140-6736(22)02302-9. Epub 2022 Dec 6. Lancet. 2023. PMID: 36493791 Clinical Trial.